Resonant X-Ray Scattering on the M-Edge Spectra from Triple-k Structure Phase in U_{0.75}Np_{0.25}O_{2} and UO_{2}

We derive an expression for the scattering amplitude of resonant x-ray scattering under the assumption that the Hamiltonian describing the intermediate state preserves spherical symmetry. On the basis of this expression, we demonstrate that the energy profile of the RXS spectra expected near U and Np M_4 edges from the triple-k antiferromagnetic ordering phase in UO_{2} and U_{0.75}Np_{0.25}O_{2} agree well with those from the experiments. We demonstrate that the spectra in the \sigma-\sigma' and \sigma-\pi' channels exhibit quadrupole and dipole natures, respectively.Comment: 3 pages, 3 figures, to be published in J. Phys. Soc. Jpn. Supp

Satellite holmium M-edge spectra from the magnetic phase via resonant x-ray scattering

Developing an expression of resonant x-ray scattering (RXS) amplitude which is convenient for investigating the contributions from the higher rank tensor on the basis of a localized electron picture, we analyze the RXS spectra from the magnetic phases of Ho near the $M_{4,5}$ absorption edges. At the $M_5$ edge in the uniform helical phase, the calculated spectra of the absorption coefficient, the RXS intensities at the first and second satellite spots capture the properties the experimental data possess, such as the spectral shapes and the peak positions. This demonstrates the plausibility of the adoption of the localized picture in this material and the effectiveness of the spectral shape analysis. The latter point is markedly valuable since the azimuthal angle dependence, which is one of the most useful informations RXS can provides, is lacking in the experimental conditions. Then, by focusing on the temperature dependence of the spectral shape at the second satellite spot, we expect that the spectrum is the contribution of the pure rank two profile in the uniform helical and the conical phases while that is dominated by the rank one profile in the intermediate temperature phase, so-called spin slip phase. The change of the spectral shape as a function of temperature indicates a direct evidence of the change of magnetic structures undergoing. Furthermore, we predict that the intensity, which is the same order observed at the second satellite spot, is expected at the fourth satellite spot from the conical phase in the electric dipolar transition.Comment: 24 pages, 5 figure

An x-ray resonant diffraction study of multiferroic DyMn2O5

X-ray resonant scattering has been used to measure the magnetic order of the Dy ions below 40K in multiferroic DyMn$_{2}$O$_{5}$. The magnetic order has a complex behaviour. There are several different ordering wavevectors, both incommensurate and commensurate, as the temperature is varied. In addition a non-magnetic signal at twice the wavevector of one of the commensurate signals is observed, the maximum intensity of which occurs at the same temperature as a local maximum in the ferroelectric polarisation. Some of the results, which bear resemblence to the behaviour of other members of the RMn$_{2}$O$_{5}$ family of multiferroic materials, may be explained by a theory based on so-called acentric spin-density waves.Comment: 8 pages, 8 figure

Multipole Ordering and Fluctuations in f-Electron Systems

We investigate effects of multipole moments in f-electron systems both from phenomenological and microscopic viewpoints. First, we discuss significant effects of octupole moment on the magnetic susceptibility in a paramagnetic phase. It is found that even within mean-field approximation, the magnetic susceptibility deviates from the Curie-Weiss law due to interactions between dipole and octupole moments. Next, we proceed to a microscopic theory for multipole ordering on the basis of a j-j coupling scheme. After brief explanation of a method to derive multipole interactions from the $f$-electron model, we discuss several multipole ordered phases depending on lattice structure. Finally, we show our new development of the microscopic approach to the evaluation of multipole response functions. We apply fluctuation exchange approximation to the f-electron model, and evaluate multipole response functions.Comment: 7 pages, 4 figures, Proceedings of ASR-WYP-200

X-ray Resonant Scattering Study of the Order Parameters in Multiferroic TbMnO3_3

We report on an extensive investigation of the multiferroic compound TbMnO$_3$. Non-resonant x-ray magnetic scattering (NRXMS) revealed a dominant $A$-type domain. The temperature dependence of the intensity and wavevector associated with the incommensurate magnetic order was found to be in good agreement with neutron scattering data. XRS experiments were performed in the vicinity of the Mn $K$ and Tb $L_3$ edges in the high-temperature collinear phase, the intermediate temperature cycloidal/ferroelectric phase, and the low-temperature phase. In the collinear phase resonant $E1-E1$ satellites were found at the Mn $K$ edge associated with $A$-type but also $F$-type peaks. The azimuthal dependence of the $F$-type satellites (and their absence in the NRXMS experiments) indicates that they are most likely non-magnetic in origin. We suggest instead that they may be associated with an induced charge multipole. At the Tb $L_3$ edge resonant $A$- and $F$-type satellites ($E1-E1$) were observed in the collinear phase. These we attribute to a polarisation of the Tb 5$d$ states by the ordering of the Mn sublattice. In the cycloidal/ferroelectric phase a new set of resonant satellites appear corresponding to $C$-type order. These appear at the Tb $L_3$ edge only. In addition to a dominant $E1-E1$ component in the $\sigma-\pi^\prime$ channel, a weaker component is found in the pre-edge with $\sigma-\sigma^\prime$ polarization. Calculations of the XRS were performed using the $FDMNES$ code showing that the unrotated $\sigma-\sigma^\prime$ component of the Tb $L_3$ $C$-type peaks appearing in the ferroelectric phase contains a contribution from a multipole that is odd with respect to both space and time, known in various contexts as the anapole.Comment: Phys. Rev. B (In press

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Background Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. Methods In this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. Findings We recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention. Interpretation Enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. Funding UK National Institute for Health Research Health Technology Assessment programme (10/57/49)

Boundary spanning at the science–policy interface: the practitioners’ perspectives

Cultivating a more dynamic relationship between science and policy is essential for responding to complex social challenges such as sustainability. One approach to doing so is to “span the boundaries” between science and decision making and create a more comprehensive and inclusive knowledge exchange process. The exact definition and role of boundary spanning, however, can be nebulous. Indeed, boundary spanning often gets conflated and confused with other approaches to connecting science and policy, such as science communication, applied science, and advocacy, which can hinder progress in the field of boundary spanning. To help overcome this, in this perspective, we present the outcomes from a recent workshop of boundary-spanning practitioners gathered to (1) articulate a definition of what it means to work at this interface (“boundary spanning”) and the types of activities it encompasses; (2) present a value proposition of these efforts to build better relationships between science and policy; and (3) identify opportunities to more effectively mainstream boundary-spanning activities. Drawing on our collective experiences, we suggest that boundary spanning has the potential to increase the efficiency by which useful research is produced, foster the capacity to absorb new evidence and perspectives into sustainability decision-making, enhance research relevance for societal challenges, and open new policy windows. We provide examples from our work that illustrate this potential. By offering these propositions for the value of boundary spanning, we hope to encourage a more robust discussion of how to achieve evidence-informed decision-making for sustainability

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Background Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. Methods In this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. Findings We recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention. Interpretation Enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. Funding UK National Institute for Health Research Health Technology Assessment programme (10/57/49)

Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies

The objective of this study was to review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), in women with menstrually related migraine (IHS criteria) through a pooled analysis of three individual studies. Subjects with a history of migraine with or without aura were randomized to F 2.5 mg or R 10 mg (study 1), F or Z 2.5 mg (study 2), and F or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double-blind, crossover design. After treating three episodes of migraine in no more than 3 months with the first treatment, patients had to switch to the next treatment for other 3 months. 346 subjects formed intention-to-treat population of the main study; 280 of them were of a female gender, 256 had regular menses and 187 were included in the menstrual migraine subgroup analysis. Rate of pain free at 2, 4 and 24 h was 23, 52 and 67 % with F and 30, 61 and 66 % with comparators (P = NS). Pain relief episodes at 2, 4 and 24 h were 37, 60 and 66 % for F and 43, 55 and 61 % for comparators (P = NS). Rate of recurrence was significantly (P < 0.05) lower under F either at 24 h (11 vs. 24 % comparators) or at 48 h (15 vs. 26 % comparators). Number of menstrual migraine attacks associated with drug-related adverse events was equally low (P = NS) between F (5 %) and comparators (4 %)